GET DAILY SIGNALSCentene (CNC) Stock: Is +11% Upside to the $76 Target Still Realistic?
Key Takeaways
- The central target of $76 is the arithmetic mean of 16 recently updated, verified analyst price targets, rounded from roughly $75.50.
- With the stock trading near $68.50, reaching $76 implies an upside of about 11%—a modest move by equity-market standards.
- Recent individual targets range widely, from about $65 (TD Cowen) to $82 (Truist and Barclays), reflecting genuine disagreement over how much improvement is already priced in.
- The strongest supports are a third-quarter 2026 earnings beat, recovering Medicaid margins, stronger ACA Marketplace pricing, and a wave of post-earnings target increases.
- The biggest risks are Medicaid membership and rate pressure, regulatory and ACA-subsidy uncertainty, and the possibility that the rally has already captured much of the recovery.
- Readers can explore Major News, Today's Price Move, a detailed Forecast, and upcoming Earnings on dedicated pages for CNC.
- For automated ideas across thousands of stocks and ETFs, explore Tickeron's Trending AI Robots.
What Analysts Are Saying About the Price Targets
The $76 central target reflects a review of the most recently updated analyst price targets that can be attributed to a named firm and analyst. These cluster between about $65 and $82, with bullish names such as Truist ($82), Barclays ($82), Argus Research ($80), and Bank of America ($80) near the top, and more cautious Hold-rated firms such as TD Cowen ($65), Jefferies ($69), Morgan Stanley ($71), Baird ($71), and RBC Capital ($71) near the bottom. UBS ($78), Cantor Fitzgerald ($79), Bernstein ($79), and Raymond James ($79) sit in between.
The overall analyst consensus leans toward Hold or a Moderate Buy, with more Hold ratings than Buy ratings. Aggregators report slightly different consensus figures—roughly $73 to $75—because they include a wider, partly older set of targets, including lower, less recently updated figures. That dispersion matters: it signals that the average target is not a guarantee, but a midpoint of genuinely divided opinions. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent actions have been broadly constructive. Argus upgraded Centene to Buy in August 2026, and Deutsche Bank moved to Buy in May 2026 citing a stabilizing managed care market and an expected recovery in earnings power beyond 2027. After the October 2026 earnings report, Wells Fargo, J.P. Morgan, and UBS all raised their targets while keeping neutral ratings—a sign that higher targets reflect modest appreciation potential rather than strong conviction the stock is deeply undervalued.
Where Centene (CNC) Stands in the Market Today
Centene's shares trade near $68.50, close to the upper end of a 52-week range that has spanned roughly $31.63 to $72.50. Moving to $76 would require an increase of about 11%, a modest step after a year in which the stock has already risen substantially.
The most direct path would be sustained improvement in the company's core government segments. Centene reported third-quarter 2026 revenue of about $50.65 billion, up roughly 1.9% year over year, and per-share earnings of $0.58 that comfortably exceeded consensus estimates. The company also narrowed its year-over-year GAAP (generally accepted accounting principles) net loss to about $71 million from more than $6.6 billion a year earlier. Continued margin recovery in Medicaid and disciplined Marketplace pricing could support further estimate revisions, which historically drive managed care share prices.
Factors That Could Help Reach the Target
- Earnings momentum and guidance: A decisive third-quarter beat and a series of post-earnings target increases suggest analysts see improving fundamentals rather than deteriorating ones.
- Medicaid margin recovery: As the largest Medicaid managed care provider, Centene benefits as pandemic-era disenrollment headwinds fade and state rates normalize.
- ACA Marketplace strength: Rising Marketplace premiums and constructive rate refilings support the individual exchange business, where Centene is a market leader.
- Valuation: Despite the rally, the stock trades near a trailing P/E (price-to-earnings ratio) in the low-to-mid 20s, which bulls argue leaves room if earnings power recovers beyond 2027.
- Analyst revision trend: Multiple firms have raised targets without downgrading, a pattern that can attract incremental buyers.
Risks That Could Keep the Target Out of Reach
- Medicaid pressure: Membership losses, rate cuts, or elevated medical cost trends in Medicaid would erode the margin recovery that underpins the bull case.
- Regulatory uncertainty: Changes to enhanced ACA premium tax credits, Medicaid work requirements, or federal funding could reset the growth outlook.
- Valuation compression: After a near-doubling in the share price, some Hold-rated analysts caution that much of the improvement may already be reflected in the current price.
- Competition: Rivals such as UnitedHealth, Elevance, Molina, and Cigna compete aggressively in government segments.
- Concentration risk: The company's heavy reliance on government programs makes it sensitive to policy shifts.
Technical Levels Worth Watching
Centene's long-term trend has been strongly upward, recovering from a 52-week low near $31.63. The stock now trades just below a notable resistance zone around the $70 to $72.50 area, which marks recent and 52-week highs. A decisive move above that zone could open a path toward the $76 target, while $65 to $66 has acted as a near-term support level during pullbacks. The round-number $70 level also carries psychological significance for traders.
Key Items to Monitor Going Forward
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms vary and do not publish identical time frames. Investors should watch the next quarterly earnings release and management's guidance, Medicaid rate decisions, ACA Marketplace rate filings, federal regulatory developments, and any further analyst revisions. Changes in medical cost trends and membership counts will be especially important for the margin story.
AI Daily Buy/Sell Signals
In my research process, I’ve found Tickeron's AI Daily Buy/Sell Signals to be a useful way to stay on top of shifting trends across a wide range of stocks. The tool applies artificial intelligence to monitor market conditions and technical behavior, helping generate Buy, Sell, or Hold signals that can complement manual analysis. It has helped me spot opportunities and monitor positions more efficiently than reviewing everything individually.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CNC in upward trend: price rose above 50-day moving average on October 09, 2026
CNC moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 39 of 56 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CNC as a result. In 56 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The 10-day moving average for CNC crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
Following a +14.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNC advanced for three days, in 186 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 132 of 213 cases where CNC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The 10-day RSI Indicator for CNC moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 18 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 60 cases where CNC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for CNC turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 30 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
CNC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. CNC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CNC's P/B Ratio (1.527) is slightly lower than the industry average of (3.520). P/E Ratio (-6.751) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (0.754) is also within normal values, averaging (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.160) is also within normal values, averaging (0.569).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a multi-line healthcare enterprise
Industry ManagedHealthCare
Advertisement